MA46337A - Composé de pyridine - Google Patents

Composé de pyridine

Info

Publication number
MA46337A
MA46337A MA046337A MA46337A MA46337A MA 46337 A MA46337 A MA 46337A MA 046337 A MA046337 A MA 046337A MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A
Authority
MA
Morocco
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
relates
compound
Prior art date
Application number
MA046337A
Other languages
English (en)
Other versions
MA46337B1 (fr
Inventor
Hiroaki Inagaki
Hideaki Kageji
Yasuyuki Kaneta
Kiyoshi Nakayama
Hidenori Namiki
Yoshihiro Shibata
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA46337A publication Critical patent/MA46337A/fr
Publication of MA46337B1 publication Critical patent/MA46337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.
MA46337A 2016-09-29 2017-09-28 Composé de pyridine MA46337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Publications (2)

Publication Number Publication Date
MA46337A true MA46337A (fr) 2019-08-07
MA46337B1 MA46337B1 (fr) 2021-04-30

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Country Status (32)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3828178A1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN113788824A (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA54910A (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI757256B (zh) 2015-11-02 2022-03-11 美商纜圖藥品公司 轉染過程重排之抑制劑
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
TW202131917A (zh) * 2019-11-18 2021-09-01 日商中外製藥股份有限公司 併用醫藥
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN117903123A (zh) * 2020-02-20 2024-04-19 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
CA3234317A1 (fr) 2021-10-22 2023-12-14 Wa Xian Methodes et compositions pour traiter une lesion inflammatoire chronique, une metaplasie, une dysplasie et des cancers des tissus epitheliaux
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
EP1994023A1 (fr) 2006-03-02 2008-11-26 AstraZeneca AB Dérivés de la quinazoline
WO2007099323A2 (fr) 2006-03-02 2007-09-07 Astrazeneca Ab Dérivés de la quinoline
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
PT2404908E (pt) * 2009-02-27 2014-06-23 Teijin Pharma Ltd Processo para a produção de um derivado heterocíclico com substituinte fenilo através de acoplamento usando catalisador de metal de transição
EP2467137A1 (fr) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Composés biaryles et procédés d utilisation de ceux-ci
EP2470173B1 (fr) 2009-08-25 2016-04-27 Abraxis BioScience, LLC Plurithérapie avec des compositions nanoparticulaires de taxane et des inhibiteurs hedgehog
WO2011133728A2 (fr) 2010-04-23 2011-10-27 Kineta, Inc. Composés antiviraux
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
EP2872493B1 (fr) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyle quinoline-2-ones utilisables en vue du traitement de l'amyotrophie spinale
NZ628388A (en) * 2013-03-15 2016-09-30 Glaxosmithkline Ip Dev Ltd Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
KR20160055170A (ko) * 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
TW201623239A (zh) * 2014-04-24 2016-07-01 田邊三菱製藥股份有限公司 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途
US9879021B2 (en) * 2014-09-10 2018-01-30 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
WO2016038552A1 (fr) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Dérivés de pyridone à titre d'inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
CN107427506A (zh) 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2992586A1 (fr) 2015-07-16 2017-01-19 Array Biopharma, Inc. Composes substitues de pyrazolo[1,5-a]pyridines comme inhibiteurs de la kinase ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
JP2019534871A (ja) 2019-12-05
RS61640B1 (sr) 2021-04-29
KR102520543B1 (ko) 2023-04-10
AU2017335242A1 (en) 2019-05-02
ZA201902232B (en) 2022-12-21
MX2019003747A (es) 2019-09-19
CA3035860A1 (fr) 2018-04-05
PL3519398T3 (pl) 2021-06-28
KR20190086442A (ko) 2019-07-22
CN113788824A (zh) 2021-12-14
US20210163464A1 (en) 2021-06-03
CY1123988T1 (el) 2022-05-27
IL265630B (en) 2021-10-31
CN110036007A (zh) 2019-07-19
EA037103B1 (ru) 2021-02-05
LT3519398T (lt) 2021-05-10
EA201990833A1 (ru) 2019-10-31
SG11201901937WA (en) 2019-04-29
CO2019004034A2 (es) 2019-07-10
PH12019500480A1 (en) 2019-08-05
IL265630A (en) 2019-05-30
PE20190805A1 (es) 2019-06-10
WO2018060714A1 (fr) 2018-04-05
MA54910A (fr) 2022-04-13
EP3828178A1 (fr) 2021-06-02
US10851092B2 (en) 2020-12-01
EP3519398B1 (fr) 2021-02-24
HUE054824T2 (hu) 2021-10-28
AU2017335242C1 (en) 2021-12-09
ECSP19030134A (es) 2019-08-30
JP2018052878A (ja) 2018-04-05
DK3519398T3 (da) 2021-03-29
UA123964C2 (uk) 2021-06-30
SI3519398T1 (sl) 2021-07-30
BR112019006047A2 (pt) 2019-06-25
CL2019000844A1 (es) 2019-06-07
EP3519398A1 (fr) 2019-08-07
CN110036007B (zh) 2021-10-15
MD3519398T2 (ro) 2021-05-31
PT3519398T (pt) 2021-03-24
AU2017335242B2 (en) 2021-08-19
HRP20210447T1 (hr) 2021-07-23
JP7098609B2 (ja) 2022-07-11
MA46337B1 (fr) 2021-04-30
ES2868748T3 (es) 2021-10-21
US20200039974A1 (en) 2020-02-06
AU2021261899A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MA46337A (fr) Composé de pyridine
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA35861B1 (fr) Inhibiteur de la kinase régulant les signaux de l'apoptose
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
MA38454B1 (fr) Inhibiteurs de protéines kinases
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
MA52948B1 (fr) Composés
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
EA202193015A1 (ru) Ингибиторы cdk
MA39983A (fr) Dérivés de carboxamide
MA50093B1 (fr) Composé pentacyclique
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
NZ746906A (en) Oxaborole esters and uses thereof
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MX2021007258A (es) Composiciones de esparsentan amorfas.
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA40605A (fr) Composé pyrazolothiazole et médicament
MA43231B1 (fr) Bloqueur des canaux sodiques
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MA38991A1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt
MA39432A (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace